Skip to content
value.today
Ensysce Biosciences, Inc. logo

Ensysce Biosciences, Inc.

ENSC
$10 Mmarket cap on Oct 19, 2026+153.0% since Jan 2024
Compare
World rank
#25,841
Revenue
$5 M
For year ending December-2025
Net income
$-10 M
-200.8% margin
SEC filing
Employees
—

Ensysce Biosciences, Inc. in brief

Ensysce Biosciences, Inc. is a listed company in the Biotechnology industry, based in La Jolla, California, USA. It was founded in 2003. Its market value was $10 M on 19 October 2026, which makes it the 25,841st largest listed company in the world and the 4,297th largest in the USA on this site. In the year to December 2025 it had sales of $5 M and a net loss of $10 M. Its largest product and service lines by sales in 2025 were MPAR (100%). Its shares trade under the symbol ENSC (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Ensysce Biosciences, Inc.

The mailing address of our principal executive office is 7946 Ivanhoe Avenue, Suite 201, La Jolla, California 92037. Our corporate telephone number is (858) 263-4196. Our website address is www.ensysce.com. Information contained on our website, or connected thereto, does not constitute part of, and is not incorporated by reference into, this Annual Report on Form 10-K.

Investors, the media, and others should note that we announce material information to the public through filings with the SEC, the investor relations page on our website, blog posts on our website, press releases, public conference calls, webcasts, and our X feed (@EnsysceBio).

From the company's annual report filed with the US SEC: read the report

Ensysce Biosciences, Inc. timeline

5 events, 2003–2024
  1. 2003
  2. 🏁
    · approximate
    Founded
  3. 2017
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 🔔
    Initial public offering as Leisure Acquisition Corp.
    Final prospectus filed with the SEC on 1 December 2017; shares registered for exchange trading on 28 November 2017. The blank-check company later merged with the business that carries the name today.
  6. 2021
  7. ✎
    Renamed Ensysce Biosciences, Inc.
    Formerly Leisure Acquisition Corp..
  8. 2024
  9. 💰
    Record revenue of $5 million
    FY2024, the highest of the 6 years on record.

Events of Ensysce Biosciences, Inc. from Wikidata, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$26 M$52 M$79 M$105 M2023202420252026

World rank over time

▼ down 2,709 places since 2022
2022-01-07: #23140#23,14020222022-12-25: #32838#32,83820222023-07-30: #32808#32,80820232024-01-05: #32974#32,97420242026-03-08: #13544#13,54420262026-08-01: #23448#23,44820262026-10-13: #25787#25,78720262026-10-19: #25849#25,8492026

Rank in USA: #4,436 (Jan 2022) · #5,759 (Dec 2022) · #5,575 (Jul 2023) · #4,656 (Jan 2024) · #2,486 (Mar 2026) · #4,099 (Aug 2026) · #4,237 (Oct 2026) · #4,299 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
1.6×
Price / book
3.2×
Free cash flow yield
-78.4%
Net margin (TTM)
-1470.3%
Operating margin
-202.0%
Return on equity
-2835.2%
Liabilities / assets
61.3%
Revenue growth
-2.7%
R&D / revenue
204.7%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $2M—FY18Fiscal year ending Dec 2019: revenue —, net income $-1M—FY19Fiscal year ending Dec 2020: revenue $4M, net income $4M$4MFY20Fiscal year ending Dec 2021: revenue $4M, net income $-29M$4MFY21Fiscal year ending Dec 2022: revenue $3M, net income $-24M$3MFY22Fiscal year ending Dec 2023: revenue $2M, net income $-11M$2MFY23Fiscal year ending Dec 2024: revenue $5M, net income $-8M$5MFY24Fiscal year ending Dec 2025: revenue $5M, net income $-10M$5MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$5M-2.7%$-10M$-10M-200.8%
Dec 2024$5M+133.6%$-7M$-8M-153.4%
Dec 2023$2M-11.5%$-11M$-11M-476.7%
Dec 2022$3M-28.6%$-24M$-24M-960.7%
Dec 2021$4M-10.2%$-20M$-29M-825.8%
Dec 2020$4M—$-2M$4M109.7%
Dec 2019——$-3M$-1M—
Dec 2018——$-1M$2M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-8M$0M$-8M$-3.98—
Dec 2024$-8M——$-11.45—
Dec 2023$-11M——$-70.40—
Dec 2022$-18M——$-139.42—
Dec 2021$-8M——$-1.48—
Dec 2020$-1M——$0.00—
Dec 2019$-1M——$-0.63—
Dec 2018$-1M——$-0.21—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$6M
Net income, trailing 12 months
$-91M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $1M, net income $-4M$1MDec ’24Three months to Mar 2025: revenue $1M, net income $-2M$1MMar ’25Three months to Jun 2025: revenue $1M, net income $-2M$1MJun ’25Three months to Sep 2025: revenue $0M, net income $-4M$0MSep ’25Three months to Dec 2025 (from the annual report): revenue $2M, net income $-3M$2MDec ’25Three months to Mar 2026: revenue $1M, net income $-4M$1MMar ’26Three months to Jun 2026: revenue $1M, net income $-3M$1MJun ’26Three months to Sep 2026: revenue $2M, net income $-82M$2MSep ’26

Latest quarter to Sep 2026: revenue $2M (+344.9% on a year earlier), net income $-82M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Ensysce Biosciences, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$5 M
Operating income
$-10 M
Net income
$-10 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$7 M
Total liabilities
$5 M
Total equity
$3 M

As of December-2025

Top 19 institutional investors in Ensysce Biosciences, Inc.#

As of Sep 30, 2026
19 institutions held 10.7 M shares (about 55.0% of the shares outstanding) on Sep 30, 2026. The ten largest hold 54.8%. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 19 largest institutional investors in Ensysce Biosciences, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Adage Capital Partners GP, L.L.C.9,471,711+9,322,000 (+6226.66%)48.68%$4 MNov 16, 2026
2Jane Street Group, LLC466,084+257,251 (+123.19%)2.40%$0 MNov 12, 2026
3Citadel Advisors LLC243,089+156,896 (+182.03%)1.25%$0 MNov 16, 2026
4StoneX Group Inc.138,563New0.71%$0 MNov 3, 2026
5Vanguard Fiduciary Trust Co110,799New0.57%$0 MNov 13, 2026
6Perceptive Advisors LLC86,6660 (0.00%)0.45%$0 MNov 16, 2026
7Geode Capital Management, LLC61,862-326 (-0.52%)0.32%$0 MNov 6, 2026
8Virtu Financial LLC41,230-54,161 (-56.78%)0.21%$0 MNov 17, 2026
9Renaissance Technologies LLC30,160New0.15%$0 MNov 12, 2026
10XTX Topco Ltd19,110-57,895 (-75.18%)0.10%$0 MNov 16, 2026
11Vanguard Capital Management LLC12,8540 (0.00%)0.07%$0 MNov 13, 2026
12Tower Research Capital LLC (TRC)6,081-13 (-0.21%)0.03%$0 MNov 16, 2026
13FNY Investment Advisers, LLC3,0000 (0.00%)0.02%$0 MOct 16, 2026
14Robinhood Markets, Inc.2,949—0.02%$0 MNov 18, 2026
15SBI Securities Co., Ltd.627-14 (-2.18%)0.00%$0 MOct 22, 2026
16Citigroup Inc456New0.00%$0 MNov 4, 2026
17Ascentis Independent Advisors80New0.00%$0 MNov 3, 2026
18BlackRock, Inc.650 (0.00%)0.00%$0 MNov 13, 2026
19UBS Group AG18New0.00%$0 MNov 10, 2026

Mutual funds holding Ensysce Biosciences, Inc.#

2 funds hold shares worth $0 M (about 0.4% of the company). Since their previous reports 1 added shares and 1 sold, buying $0 M net.
Mutual funds holding Ensysce Biosciences, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC72,454$0 M0.37%<0.01%+276%May 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.12,854$0 M0.07%<0.01%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 2 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Ensysce Biosciences, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$444 K
2 purchases, 1 insider
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$444 K
open market only
Insiders on file
11
since
$244 K$0Apr 2026: bought $244 K (1 trades), sold $0 (0 trades)Apr 26Aug 2026: bought $200 K (1 trades), sold $0 (0 trades)Aug
Bought (open market)Sold (open market)Hover a month for the totals
Ensysce Biosciences, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Bob G. GowerDirectorBuy+400,000$0.500$200 K916,740Form 4
filed Bob G. GowerDirectorBuy+508,614$0.480$244 K516,740Form 4
filed Bob G. GowerDirectorBuy+90,287$0.490$44 K1.22 MForm 4
filed Bob G. GowerDirectorBuy+270,000$0.480$130 K1.13 MForm 4
filed Bob G. GowerDirectorBuy+109,300$0.490$54 K862,395Form 4
filed Bob G. GowerDirectorBuy+357,143$1.400$500 K753,095Form 4
filed Lynn KirkpatrickChief Executive Officer, DirectorBuy+27,000$0.530$14 K381,851Form 4
filed Lynn KirkpatrickChief Executive Officer, DirectorBuy+70,000$0.490$34 K354,851Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Ensysce Biosciences, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
88,607
1.9% of shares · 1 days to cover
Buybacks, Q1 2020
$136.3M
Q1 2020
Shares sold short, last 24 reportsAll stocks →
Ensysce Biosciences, Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q1 2020Q1 2020$136.3M

Trading halts

  • 2026-08-06 13:42 UTC, code LUDP, resumed 13:47 UTC
  • 2024-12-16 17:04 UTC, code LUDP, resumed 17:09 UTC
  • 2024-12-16 16:52 UTC, code LUDP, resumed 16:57 UTC
  • 2024-12-16 16:23 UTC, code LUDP, resumed 16:28 UTC
  • 2024-12-16 16:18 UTC, code LUDP, resumed 16:23 UTC

Fails to deliver

  • : 16 shares at $0.52
  • : 3,288 shares at $0.56
  • : 102,019 shares at $0.56
  • : 111,316 shares at $0.46
  • : 10,464 shares at $0.43

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Ensysce Biosciences, Inc. scorecard#

Passes 5 of the 20 checks that could be worked out: strongest in growth (2 of 6), weakest in valuation (1 of 5). Fiscal year 2025; market cap of Oct 19, 2026.

  • Valuation1 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median3.1×Price to book 3.1× against Biotechnology's median of 2.9×.
    • ✓Price to sales below its peers' median1.6×Price to sales 1.6× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-78.4%Free cash flow is -78.4% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth2 of 6
    • ✗Revenue grew in the newest year-2.7%Revenue down 2.7% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years26.2%26.2% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median26.2%26.2% a year against Biotechnology's median of 12.9% (181 companies).
    • ✗Earnings per share grew in the newest year-3.98 vs -11.45Diluted EPS -3.98 in fiscal 2025 against -11.45 the year before (report's currency).
    • ✗Net income higher than five years earlier-$10 M-$10 M in fiscal 2025 against $4 M in 2020.
    • ✗Revenue rose in at least four of the last five years1 of 5Revenue rose in 1 of the five years to fiscal 2025.
  • Profitability1 of 5
    • ✗Profitable in the newest year-$10 MNet income -$10 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-202.0%-202.0% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%-294.2%-294.2% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-202.0%-202.0% in fiscal 2025 against -961.1% in 2022.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities1.6×Current ratio 1.59 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-28.35Z-score -28.35 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year266.3%Diluted shares up 266.3% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Ensysce Biosciences, Inc.'s statements, beside the median of Biotechnology.

Ensysce Biosciences, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-202.0%-60.5%
Net margin-200.8%-68.9%
Return on equity-294.2%-61.0%
Revenue growth, 3 years a year26.2%12.9%
Revenue growth-2.7%15.8%
Free cash flow margin-156.4%-61.5%

2of 7on the Piotroski tests of financial strength

  • Revenue fell 2.7% against the year before.
  • Net loss of $10 million, the 5th loss-making year in a row.
  • Free cash flow was negative: -$8 million.
  • The share count rose 266.3% in the year.

Ensysce Biosciences, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Ensysce Biosciences, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018
Income statement
Revenue5.15.22.22.53.53.9——
Research and development107.27.6204.74.4——
Selling, general and administrative————191.2——
General and administrative4.94.75.46.919———
Operating expenses15121327235.5r3.31.6
Operating income−10−6.7−11−24−20−1.6r−3.3−1.0
Interest and finance income—————0.74.23.6
Interest expense and finance costs0.01.30.40.11.31.0——
Provision for credit losses——−0.0−0.0−0.00.0——
Other non-operating income (expense)0.1−1.30.10.0−9.31.5——
Income before tax—————4.6r−0.5r2.7
Income tax—————0.20.60.6
Net income including minority interests−10−8.0−11−24−29−0.2r−1.1r2.1
Minority interests' share of net income−0.0−0.0−0.0−0.0−0.1−0.2——
Net income attributable to shareholders—————4.3r−1.1r2.1
Earnings per share, basic-3.98-11.45-70.40r-139.42r-29.64r0.00r-0.63r-0.21r
Earnings per share, diluted-3.98-11.45-70.40r-139.42-1.480.00r-0.63r-0.21r
Shares, weighted average (basic)2.60.70.2r0.2r1.0r16——
Shares, weighted average (diluted)2.60.70.2r0.22017r6.6r6.6r
Balance sheet
Cash and cash equivalents4.33.51.13.1120.2r1.11.7
Other current assets0.0r0.00.01.8————
Current assets7.2r5.32.35.3160.3r1.21.9
Property, plant and equipment0.1————0.0——
Right-of-use (leased) assets—————0.0——
Total assets7.55.62.75.9160.4r197205
Accounts payable3.31.41.92.90.31.7r2.80.4
Current liabilities4.62.23.39.5167.0r2.8r0.4
Non-current liabilities—0.00.00.58.1———
Total liabilities4.62.23.49.9257.0r18r13r
Retained earnings−140−130−122−111−86−56r−0.1r0.9r
Shareholders' equity3.23.7−0.3−3.7−7.9−6.4r5.05.0
Minority interests−0.3−0.3−0.3−0.3−0.3−0.2——
Total equity2.93.4−0.7−4.0−8.2−6.7−6.7—
Total liabilities and equity7.55.62.75.9160.4r197205
Shares outstanding4.61.40.2r0.5r1.2r16r7.1r6.0
Cash-flow statement
Share-based compensation0.20.10.91.10.10.2——
Cash from operating activities−7.8−7.5−11−18−8.2−1.2r−1.4−1.2
Capital expenditure−0.1———————
Cash from investing activities−0.1——0.0—183120.8
Debt issued————16———
Shares issued————6.6−185−12—
Shares bought back—————−185−12—
Cash from financing activities8.79.98.88.8201.1r−11−0.0
Change in cash0.82.4−2.0−9.112−0.1r−0.6−0.4
Report10-K10-K10-K10-K10-K10-K10-K/A10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Ensysce Biosciences, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • MPAR$5 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Executive pay at Ensysce Biosciences, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$487 K
Dr. Lynn Kirkpatrick
Other top executives, average
$394 K
the CEO earned 1.2× this
$100 invested is now
$1
Ensysce Biosciences, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Dr. Lynn Kirkpatrick$487 K$470 K$394 K$1
2024Dr. Lynn Kirkpatrick$442 K$442 K$357 K$6
2023Dr. Lynn Kirkpatrick$509 K$507 K$417 K$12

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Ensysce Biosciences, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Auditor changedFiling

Delisting notice 2 · Auditor changed 1 · Acquisition or sale completed 1 · Directors and officers 5 · Material agreement 6 · Unregistered share sale 5 · Shareholder rights changed 1 · Bylaws or fiscal year changed 5 · Shareholder vote 1 · Results announced 8

Ensysce Biosciences, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Directors and officers8-K
Bylaws or fiscal year changed8-K
Results announced8-K
Acquisition or sale completedDirectors and officersMaterial agreementUnregistered share saleShareholder rights changedBylaws or fiscal year changed8-K
Directors and officers8-K
Delisting notice8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Bylaws or fiscal year changed8-K
Delisting notice8-K
Shareholder vote8-K
Material agreementUnregistered share saleBylaws or fiscal year changed8-K
Results announced8-K
Results announced8-K
Auditor changed8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Material agreement8-K
Bylaws or fiscal year changed8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Ensysce Biosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2026$77 MPrivate placement after listing$50 to $250 million44equitySEC
Apr 2025$2 MPrivate placement after listing$2 to $10 million8optionsSEC
Mar 2025$1 MPrivate placement after listingUnder $2 million8optionsSEC
Aug 2024$5 MPrivate placement after listing$2 to $10 million4optionsSEC
Feb 2024$5 MPrivate placement after listing$2 to $10 million4optionsSEC
Feb 2023$3 MPrivate placement after listing$2 to $10 million8optionsSEC
Jun 2022$4 MPrivate placement after listing$2 to $10 million3debt, optionsSEC
Sep 2021$5 MPrivate placement after listing$2 to $10 million3debt, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Ensysce Biosciences, Inc. compares in Biotechnology

  • Market cap$10 M · higher than 11% of 726
  • Revenue$5 M · higher than 36% of 647
  • Revenue growth-2.7% · higher than 40% of 438
  • Price / sales1.6× · lower than 88% of 339
  • Price / book3.1× · lower than 47% of 534
  • FCF yield-78.4% · higher than 14% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Ensysce Biosciences, Inc.🇺🇸$10 M——-2.7%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 19, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 19, 2026

Figures from Market data, SEC filing, Wikidata, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Ensysce Biosciences, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Ensysce Biosciences, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Ensysce Biosciences, Inc.? Suggest a correction